ArticleCancers2025

CRISPR-Cas9 Genome and Double-Knockout Screening to Identify Novel Therapeutic Targets for Chemoresistance in Triple-Negative Breast Cancer.

Shuai Shao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.